Normal view MARC view ISBD view

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.

In Cancer Cell
By: Pahuja KB.
Contributor(s): Nguyen TT | Jaiswal BS | Prabhash K | Thaker TM | Senger K | Chaudhuri S | Kljavin NM | Antony A | Phalke S | Kumar P | Mravic M | Stawiski EW | Vargas D | Durinck S | Gupta R | Khanna-Gupta A | Trabucco SE | Sokol ES | Hartmaier RJ | Singh A | Chougule A | Trivedi V | Dutt A | Patil V | Joshi A | Noronha V | Ziai J | Banavali SD | Ramprasad V | DeGrado WF | Bueno R | Jura N | Seshagiri S [Corresponding author].
Material type: materialTypeLabelArticlePublisher: 2018Description: .Subject(s): ERBB2 activation | ERBB2 structure | ERBB2/HER2 | HER2 germline mutation | HER2 kinase inhibitors | HER2 somatic mutation | anti-HER2 antibodies | Juxtamembrane (JMD) domain mutation | Transmembrane domain (TMD) mutation In: Cancer Cell Vol. 34, no. 5, p. 792-806Summary: Abstract Deregulated HER2 is a target of many approved cancer drugs. We analyzed 111,176 patient tumors and identified recurrent mutations in HER2 transmembrane domain (TMD) and juxtamembrane domain (JMD) that include G660D, R678Q, E693K, and Q709L. Using a saturation mutagenesis screen and testing of patient-derived mutations we found several activating TMD and JMD mutations. Structural modeling and analysis showed that the TMD/JMD mutations function by improving the active dimer interface or stabilizing an activating conformation. Further, we found that HER2 G660D employed asymmetric kinase dimerization for activation and signaling. Importantly, anti-HER2 antibodies and small-molecule kinase inhibitors blocked the activity of TMD/JMD mutants. Consistent with this, a G660D germline mutant lung cancer patient showed remarkable clinical response to HER2 blockade.
TMC TMH
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR19238

Address for correspondence: sekar@gene.com.

Abstract
Deregulated HER2 is a target of many approved cancer drugs. We analyzed 111,176 patient tumors and identified recurrent mutations in HER2 transmembrane domain (TMD) and juxtamembrane domain (JMD) that include G660D, R678Q, E693K, and Q709L. Using a saturation mutagenesis screen and testing of patient-derived mutations we found several activating TMD and JMD mutations. Structural modeling and analysis showed that the TMD/JMD mutations function by improving the active dimer interface or stabilizing an activating conformation. Further, we found that HER2 G660D employed asymmetric kinase dimerization for activation and signaling. Importantly, anti-HER2 antibodies and small-molecule kinase inhibitors blocked the activity of TMD/JMD mutants. Consistent with this, a G660D germline mutant lung cancer patient showed remarkable clinical response to HER2 blockade.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha